固定剂量复合剂治疗初治涂阳肺结核效果分析  

Analysis on the effect of fixed-dose combination in the initial treatment for patients with smear-positive pulmonary tuberculosis

作　　者：聂志学 应潜 汪仕文 赖建萍[1] 陈小菁 王坚[1] 王自扬 

机构地区：[1]江西省鹰潭市疾病预防控制中心,江西鹰潭335001 [2]鹰潭市人民医院

出　　处：《现代预防医学》2012年第8期2043-2046,共4页Modern Preventive Medicine

基　　金：鹰科社发支撑应用技术研究与开发(疾病防治技术研究)(2009-2060402-10)

摘　　要：目的评价国产抗结核固定剂量复合剂(FDC)的临床效果、安全性和可行性。方法将184例初治涂阳肺结核患者分为研究组(FDC)和对照组(组合药),并进行临床应用对比分析研究。结果研究组与对照组:治愈率分别为96.7%、89.1%,停药率为2.2%、9.8%(均P﹤0.05);治疗依从性在药物接受程度、服药感受和方式方面,研究组均优于对照组(前两者P﹤0.01,后者P﹤0.05);痰检转阴率、X线胸片改变率和不良反应发生率两组差异均P﹥0.05。药品总用量FDC比组合药在强化期减少42.14%,继续期却增加86.96%。治愈1例病人平均成本FDC比组合药增加99.7%。结论 FDC在治愈率、停药率和治疗依从性以及减少耐药方面比组合药更显优势,可以在国内推广应用,但也需要做一些改进。OBJECTIVE To evaluate the clinical effect,security and feasibility of domestic fixed-dose combination（FDC）in tuberculosis treatment.METHODS 184 examples of initial smear-positive pulmonary tuberculosis patients were assigned to the case group by using FDC and the control group by using the blister pack.We used comparative analysis for the clinical application.RESULTS Compared with he case group and the control group,the cure rate respectively was 96.7% and 89.1%,respectively;The stopped treatment rate was 2.2% and 9.8%,respectively,（both were P﹤0.05）.The case group was superior to the control group in the acceptable degree of drug,the feeling of taking drugs and the methods（the first two：P﹤0.01,and the last two：P﹤0.05）.The rate of the sputum convert to negative,change in X line chest radiography and the side-effect did not show significant difference（the above：P﹥0.05）.Using FDC was reduced by 42.14%than that of the combination drug in the intensive phase,but increased by 86.96%in the consolidation period.The average cost of FDC for curing one patient was significantly increased by 99.7%.CONCLUSION FDC has obvious advantage in cure rate,stopped treatment rate,patient＇s compliance and reducing tuberculosis patients of drug resistance.FDC may be promoted and applied in the domestic,but it needs to be done some improvement.

关 键 词：结核 肺 抗结核药 固定剂量复合剂 

分 类 号：R521[医药卫生—内科学]